Core Viewpoint - cbdMD, Inc. has regained full compliance with the NYSE American listing standards, leading to the removal of the ".BC" indicator for noncompliance effective December 8, 2025 [1][2]. Group 1: Compliance and Financial Position - The NYSE American confirmed in a letter dated December 5, 2025, that cbdMD resolved all deficiencies related to Sections 1003(a)(i) and (ii) of the NYSE American Company Guide [2]. - The CEO of cbdMD, Ronan Kennedy, emphasized that maintaining the NYSE American listing was a critical achievement, reflecting the company's efforts to strengthen its balance sheet and position for sustainable growth [3]. - Key components of cbdMD's compliance strategy included a successful Series A Preferred share conversion in May and a capital raise completed in September, showcasing investor commitment to the company's long-term vision [3]. Group 2: Future Commitment - The company will continue to be subject to NYSE American's ongoing listing monitoring procedures and is committed to maintaining strong financial discipline and governance moving forward [3]. - Additional information regarding the compliance and financial status will be available in the Company's Form 8-K to be filed with the Securities and Exchange Commission on December 8, 2025 [4]. Group 3: Company Overview - cbdMD, Inc. is recognized as a leading brand in the cannabidiol (CBD) market, offering a comprehensive line of U.S. produced CBD products and Farm Act compliant Delta 9 products [5]. - The company's product range includes veterinarian-formulated pet products under the Paw CBD brand, Herbal Oasis THC Seltzer, and ATRx brand of natural functional mushroom support [5].